A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

NCT07169994 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

414

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Breast Cancer
Non Small Cell Lung Cancer

Interventions

DRUG: YL202 for injection; Toripalimab injection
DRUG: YL202 for injection; Furmonertinib Mesilate Tablets

Sponsor

MediLink Therapeutics (Suzhou) Co., Ltd.